A big plus for Roche today after the European Commission issued a final positive decision for its once- or twice-monthly anaemia drug Mircera for use in chronic kidney disease patients that is valid ...

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

ZURICH (MarketWatch) -- Roche Holding AG RHHBY Thursday said its anemia drug Mircera, a follow-up to a blockbuster that's losing patent protection, received approval to be sold in the European Union ...

ZURICH, April 13 (Reuters) - Swiss drugmaker Roche's experimental medicine Mircera is safe and effective for the treatment of renal anaemia associated with chronic kidney disease, pooled data from ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

New data for Roche’s anaemia drug Mircera confirm that the drug can raise haemoglobin levels in the blood with twice-monthly dosing, suggesting it will mount a strong challenge to current treatments ...

Please provide your email address to receive an email when new articles are posted on . It is an exciting time in the treatment of renal anemia, with several new therapies recently launched or ...

It's a victory, but there won't be any party. Roche got the FDA's blessing for its anemia drug Mircera--an event long anticipated by the Swiss drug maker. Instead of moving Mircera quickly onto store ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...

Roche Pharmaceuticals quickly rejected claims that Roche planted secret molecule in Mircera which allowed for detection of the CERA class drug at the 2008 Tour de France. John Fahey, WADA president, ...

Should he or shouldn't he? The judge weighing the case of Amgen v. Roche is getting a lot of unsolicited advice on whether to allow Roche's anemia med Mircera onto the market. Last year, a jury ruled ...